NOD2 Antibody
Code | Size | Price |
---|
PSI-2513-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-2513-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
NOD2 Antibody: CD, ACUG, BLAU, IBD1, NLRC2, NOD2B, CARD15, CLR16.3, PSORAS1, Nucleotide-binding oligomerization domain-containing protein 2, Caspase recruitment domain-containing protein 15
Application Note:
NOD2 antibody can be used for detection of Noxa by Western blot at 2 to 4 μg/mL. Antibody can also be used for immunocytochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
NOD2 Antibody: Apaf-1 and NOD1 are members of a new family, which are involved in the regulation of apoptosis and immune response. Each of them contains a caspase recruitment domain (CARD) and a nucleotide-binding oligomerization domain (NOD). A third member in this family was recently identified and designated NOD2. NOD2 interacts with RICK via a homophilic CARD-CARD interaction. NOD2 activates NF-κB, which is regulated by its carboxy-terminal leucine-rich repeat domain that acts as an intracellular receptor for components of bacteria. The variants of NOD2, either a frameshift or a missense, were associated with Crohn's disease that is a main type of chronic inflammatory bowel disease.
Background References:
- Inohara N, Koseki T, del Peso L, et al. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-κB. J. Biol. Chem. 1999; 274:14560-7.
- Ogura Y, Inohara N, Benito A, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB. J. Biol. Chem. 2001; 276:4812-8.
- Hugot JP, Chamaillard M, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603.
- Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-6.
Buffer:
NOD2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (77%), Mouse: (77%)
Immunogen:
Rabbit NOD2 polyclonal antibody was raised against a synthetic peptide corresponding to 14 amino acids at the carboxy terminus of human NOD2.
The immunogen is located within the last 50 amino acids of NOD2.
The immunogen is located within the last 50 amino acids of NOD2.
NCBI Gene ID #:
64127
NCBI Official Name:
nucleotide-binding oligomerization domain containing 2
NCBI Official Symbol:
NOD2
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
114 kDa
Protein Accession #:
Q9HC29
Protein GI Number:
20137973
Purification:
NOD2 Antibody is immunoaffinity chromatography purified IgG.
Research Area:
Apoptosis
SPECIFICITY:
NOD2 has no cross-reaction with NOD1.
Swissprot #:
Q9HC29
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
Product Name | Product Code | Supplier | NOD2 Peptide | PSI-2513P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|